The Russian Direct Investment Fund (RDIF) and Adienne Pharma & Biotech signed an agreement on the production of the Sputnik V vaccine in Italy, RIA Novosti reported, citing a press release from the Italian-Russian Chamber of Commerce.
“For the first time in Europe, an agreement was signed between the Russian State Direct Investment Fund (RDIF) and Adienne Pharma & Biotech on the production of the Sputnik V vaccine in Italy,” the Italian-Russian Chamber of Commerce said in a statement.
According to her, the local production of the Sputnik V vaccine is due to begin in July.
“This solution will create new jobs and fully control the production process of the drug. It is planned to produce 10 million doses by the end of the year, “the report says.
The Sputnik V vaccine was registered by the Russian Ministry of Health in August 2020, it was developed by the Gamalei Research Center. The scientific journal Lancet published results from III phase of clinical studies of the vaccine. During of this phase of clinical research, Sputnik V showed high rates of efficacy (91.6%), immunogenicity and safety. As noted by the CEO of the Hamalei center, Alexander Ginzburg, the Russian vaccine provides 100% protection against severe and moderate cases of coronavirus infection.